The abstract is read at the publisher; the summary is JClub's.
Upacicalcet given intravenously to hemodialysis patients with secondary hyperparathyroidism reduced intact parathyroid hormone by ≥30% in 42% and 44% versus 17% and 17% on placebo.
- Why it matters: Secondary hyperparathyroidism is common in chronic kidney disease on hemodialysis, and clinicians need effective, well-tolerated options to lower iPTH while managing calcium-related risks.
- What they did: In two parallel phase 3, double-blind, placebo-controlled trials (PATH-1 and PATH-2) in 768 patients with iPTH 400–1500 pg/ml, participants received upacicalcet or placebo for 27 weeks with iPTH- and calcium-guided titration.
- The result: PATH-1 and PATH-2 showed strata-adjusted iPTH attenuation of 42.1% vs 16.8% and 43.5% vs 17.4% (both P < 0.001), with more corrected calcium <7.5 mg/dl and dose interruptions on upacicalcet, while serious adverse events and gastrointestinal events were similar.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.